Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy

Published:2019-10 Issue:10 Volume:14 Page:e236-e237
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Huang Yihua,Gan Jiadi,Guo Kunbin,Deng Yangyang,Fang Wenfeng

Funder

National Key R&D Program of China

Chinese National Natural Science Foundation

Science and Technology Program of Guangdong

Science and Technology Program of Guangzhou

Chinese Academy of Sciences

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations;Paik;J Clin Oncol,2011

2. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non–small cell lung cancer: an open-label, multicentre phase 2 trial;Planchard;Lancet Oncol,2016

3. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non–small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol,2017

4. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib;Ho;J Thorac Oncol,2017

5. EGFR L792H and G796R: two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib;Zhang;J Thorac Oncol,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09

2. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E;OncoTargets and Therapy;2024-04

3. Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives;The Journal of Liquid Biopsy;2024-03

4. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations;Anti-Cancer Drugs;2023-08-15

5. Targeted Therapy for Non–Small Cell Lung Cancer;Hematology/Oncology Clinics of North America;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3